We are a Venture Capital fund that invests in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus on ALS

Neurodegeneration is the leading cause of death and disability

1 in 5 people will get a neurodegenerative disease

1 in 350 people will get ALS - as many as Multiple Sclerosis

But the tide is turning: Neurodegenerative diseases can become a managed condition

Experts: New drugs could dramatically improve quality of life within the next decade by preserving cognition and motor function

We are supporting & backing extraordinary people,

working to change the course of neurodegenerative diseases

After 10 successful years we are convinced that our joint efforts will help us accelerate the new generation of therapies

Amylyx is a commercial stage company developing proprietary therapeutics for Amyotrophic Lateral Sclerosis and other neurodegenerative diseases. ALS IF exited the company in 2023.

Learn more
Apic Bio Inc. (”Apic”) is a Boston based gene therapy company with a clinical stage program and a new, ground breaking technology platform. KIID (EID) DUTCH, KIID (EID) ENG

Learn more
Bloom Science is a clinical-stage biotech company advancing a deep pipeline of programs that target the Gut-Brain axis for indications including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.KIID (EID) DUTCH, KIID (EID) ENG

Learn more
The platform offers researchers a new standard for predicting how a human may respond to medicines, chemicals, and foods — with greater precision and control than today’s cell culture or animal-based testing methods. KIID (EID) DUTCH, KIID (EID) ENG

Learn more
Orphazyme was founded in 2009 with the objective to develop new therapies for patients suffering from protein-misfolding diseases with no or limited treatment options available. ALS IF exited the company in 2022.

Learn more
Prilenia is a clinical stage biotech company, founded by the former President of Global R&D and CSO of Teva, with 2 late stage programs for ALS and Huntington's disease currently in development. KIID (EID) DUTCH, KIID (EID) ENG

Learn more
ProJenX was founded in 2021, a spin-out from Columbia University and Project ALS, based on robust scientific evidence of MAP4 kinases being critical regulators of motor neuron loss in ALS. The company is currently conducting a Ph1 clinical study.

Learn more
QurAlis is a clinical stage biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases.KIID (EID) DUTCH,KIID (EID) ENG

Learn More
Verge is a clinical stage biotech company that was founded on the belief that exponential advances in computational genomics, combined with new insights in neuroscience, will lead to breakthrough opportunities to identify targets and discover drugs that can dramatically improve the lives of patients suffering from neurodegenerative diseases. KIID (EID) DUTCH,KIID (EID) ENG

Learn more
VectorY is an Amsterdam-based biotech company founded in 2020 with a mission to develop vectorized antibody treatments for people with neurodegenerative diseases, enabling longer, better lives. KIID (EID) DUTCH, KIID (EID) ENG

Learn more